Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Inclusion Criteria: * Male and/or female subjects 18 years or older with chronic pruritus of moderate to severe severity in the setting of intrahepatic or extrahepatic cholestatic liver disease. Chronic is defined as greater than 6 weeks of symptom duration. Pruritus severity is based on the peak pruritus numerical rating score of ≥ 4 (moderate severity). * Documentation of a personally signed and dated informed consent indicating that the subject or their legally acceptable representative has been informed of all pertinent aspects of the trial. * Willingness and ability to comply with scheduled clinic visits, physical exams, laboratory tests, questionnaires, effective contraception use, and other trial procedures. Exclusion Criteria: * Male and/or female subjects under 18 years of age. * Pruritus due to a primary inflammatory skin dermatosis or other forms of psychogenic pruritus utilizing skin biopsies as needed. * Pregnant females * History of intrahepatic cholestasis of pregnancy * Any form of chronic hepatic pruritus associated with underlying malignancy * Liver transplant recipients * Allergy to dupilumab or its ingredients * Inability to provide informed consent * Concomitant use of selective opioid antagonists * Subjects with severe asthma (requiring high-dose inhaled or systemic corticosteroids) will be excluded from the study. * Patients with known helminth infections